@article{ref1,
title="How does gender-affirming hormone therapy affect QOL in transgender patients?",
journal="Journal of family practice",
year="2022",
author="Wilhelm, Sarah and Kelsberg, Gary and Safranek, Sarah",
volume="71",
number="10",
pages="442-444",
abstract="There are modest effects on depression but not anxiety. Gender-affirming hormone therapy (GAHT) is associated with modest improvements in standardized scores for quality of life (QOL) and depression in adult male-to-female and female-to-male transgender people and modest improvements in depression scores in transgender adolescents, but the effect on anxiety is uncertain (strength of recommendation [SOR]: B, based on a preponderance of low-quality prospective cohort studies with inconsistent results). GAHT is associated with reduced gender dysphoria and decreased suicidality (SOR: B, based on a prospective cohort study). However, there is insufficient evidence to determine any effect on suicide completion. No studies associated GAHT with worsened QOL, depression, or anxiety scores.<p /> <p>Language: en</p>",
language="en",
issn="0094-3509",
doi="10.12788/jfp.0521",
url="http://dx.doi.org/10.12788/jfp.0521"
}